Who are in the management team of Archean Chemical?

As of March 2023, the management team of Archean Chemical includes P. Ranjit (Managing Director), Subrahmanyam Meenakshisundaram, P Ravi (Directors), and three Independent Directors: Padma Chandrasekaran, C G Sethuram, and Kandheri Munuswamy Mohandass, along with G Arunmozhi (Company Secretary & Compliance Officer).

As of March 2023, the management team of Archean Chemical includes the following individuals:<BR><BR>1. **P. Ranjit** - Managing Director<BR>2. **Subrahmanyam Meenakshisundaram** - Director<BR>3. **P Ravi** - Director<BR>4. **Padma Chandrasekaran** - Independent Director<BR>5. **C G Sethuram** - Independent Director<BR>6. **Kandheri Munuswamy Mohandass** - Independent Director<BR>7. **G Arunmozhi** - Company Secretary & Compliance Officer<BR><BR>Each member plays a crucial role in the governance and operational management of the company.

Has Archean Chemical declared dividend?

Yes, Archean Chemical Industries Ltd has declared a 150% dividend, amounting to ₹3 per share, with an ex-date of May 26, 2025. The dividend yield is 0.63%, and while recent total returns have varied, the company has shown positive returns over the longer term.

Archean Chemical Industries Ltd has declared a 150% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 150%<BR>- Amount per share: 3<BR>- Ex-date: May 26, 2025<BR><BR>Dividend Yield: 0.63%<BR><BR>Total Returns by Period:<BR>Over the last 6 months, the price return was -7.19%, the dividend return was 0.43%, resulting in a total return of -6.76%.<BR><BR>In the past year, the price return was 5.72%, the dividend return was 0.64%, leading to a total return of 6.36%.<BR><BR>For the 2-year period, the price return was 9.71%, the dividend return was 1.53%, culminating in a total return of 11.24%.<BR><BR>Over the last 3 years, there was no price return and no dividend return, resulting in a total return of 0.0%.<BR><BR>In the 4-year period, there was also no price return and no dividend return, leading to a total return of 0.0%.<BR><BR>For the 5-year period, the price return and dividend return remained at 0%, resulting in a total return of 0.0%.<BR><BR>Overall, Archean Chemical has declared a significant dividend, and while the recent total returns show variability, the company has managed to provide positive returns over the longer term despite some periods of stagnation.

Is Archean Chemical overvalued or undervalued?

As of November 22, 2022, Archean Chemical is considered very expensive and overvalued with a PE Ratio of 41.74 and an EV to EBITDA of 25.16, despite outperforming the Sensex recently, indicating it may not be a compelling investment at its current price of 644.70.

As of 22 November 2022, the valuation grade for Archean Chemical moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued based on its financial ratios, which include a PE Ratio of 41.74, an EV to EBITDA of 25.16, and a Price to Book Value of 4.25. These figures suggest that the stock is trading at a premium compared to its earnings and assets.<BR><BR>In comparison to its peers, Archean Chemical's PE Ratio is notably lower than Solar Industries India Ltd., which has a PE of 123.77, but higher than Godrej Industries Ltd. at 46.63. Additionally, the EV to EBITDA ratio of Archean is higher than that of Deepak Nitrite Ltd. at 24.57, further supporting the notion of overvaluation. Despite a recent strong performance relative to the Sensex, with a 1-month return of 15.95% compared to the Sensex's 3.81%, the overall valuation metrics indicate that Archean Chemical is not a compelling investment at its current price of 644.70.

Who are the peers of the Archean Chemical?

Archean Chemical's peers include Alkyl Amines, Aether Industries, Elantas Beck, and others, with varying management risks and growth ratings. Camlin Fine leads in 1-year returns at 141.62%, while Archean Chemical's return is -1.86%.

Peers: The peers of Archean Chemical are Alkyl Amines, Aether Industri., Elantas Beck, Privi Speci., Galaxy Surfact., Epigral, Balaji Amines, Styrenix Perfor., Camlin Fine, and Laxmi Organic.<BR><BR>Quality Snapshot: Excellent management risk is observed at Alkyl Amines and Styrenix Perfor., while Good management risk is found at Elantas Beck, Galaxy Surfact., Archean Chemical, and Epigral. Average management risk is present at Privi Speci. and Balaji Amines, and Below Average management risk is noted for Aether Industri. and Camlin Fine. Growth is rated as Below Average for all peers except for Styrenix Perfor., which has Good growth. Capital Structure is Excellent for Alkyl Amines, Galaxy Surfact., Archean Chemical, Balaji Amines, and Styrenix Perfor., while it is Good for Epigral, and Below Average for Privi Speci. and Camlin Fine.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Camlin Fine at 141.62%, while the lowest is Aether Industri. at -9.58%. Archean Chemical's 1-year return is -1.86%, which is higher than Aether Industri. but lower than Camlin Fine. Additionally, Galaxy Surfact. and Laxmi Organic have negative six-month returns.

What does Archean Chemical do?

Archean Chemical Industries Ltd is a mid-cap company in the specialty chemicals sector, reporting net sales of ₹3,456 Cr and a net profit of ₹535 Cr for Q1 2025. Key metrics include a P/E ratio of 45.00 and a market cap of ₹8,594 Cr.

Overview:<BR>Archean Chemical Industries Ltd operates in the specialty chemicals industry and is categorized as a mid-cap company.<BR><BR>History:<BR>The company was originally formed as a Partnership Firm under the name "Archean Chemical Industries" in Chennai, pursuant to a Partnership Deed dated November 20, 2003. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 3,456 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 535 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 8,594 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: 45.00 <BR>Industry P/E: 47 <BR>Dividend Yield: 0.43% <BR>Debt Equity: -0.01 <BR>Return on Equity: 10.19% <BR>Price to Book: 4.62 <BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the top shareholders of the Archean Chemical?

The top shareholders of Archean Chemical include Chemikas Speciality LLP with 30.54%, mutual funds at 15.56% (led by SBI Small Cap Fund at 6.88%), foreign institutional investors at 10.94%, and individual investors holding 9.52%. Additionally, there is a pledged promoter holding of 6.974%.

The top shareholders of Archean Chemical include a mix of promoters, mutual funds, and foreign institutional investors (FIIs). The majority shareholders are the promoters, with Chemikas Speciality LLP holding the largest stake at 30.54%. Additionally, mutual funds collectively hold 15.56% of the company, with the SBI Small Cap Fund being the highest public shareholder at 6.88%. FIIs account for 10.94% of the shares, and individual investors hold 9.52%. Notably, there is a pledged promoter holding of 6.974%.

How big is Archean Chemical?

As of 24th July, Archean Chemical Industries Ltd has a market capitalization of 8,544.00 Cr, with Net Sales of 1,041.02 Cr and a Net Profit of 162.15 Cr for the latest four quarters. Shareholder's Funds are 1,864.01 Cr and Total Assets are 2,389.03 Cr as of March 2025.

As of 24th July, Archean Chemical Industries Ltd has a market capitalization of 8,544.00 Cr, categorizing it as a Mid Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 1,041.02 Cr and a Net Profit of 162.15 Cr.<BR><BR>For the latest annual period ending March 2025, Shareholder's Funds amounted to 1,864.01 Cr, while Total Assets were reported at 2,389.03 Cr.

Are Archean Chemical latest results good or bad?

Archean Chemical's latest results show strong sales growth with a 41.1% increase in net sales, but a concerning 36.21% decline in profit after tax and a decrease in the debtors turnover ratio indicate underlying challenges. Overall, the results are mixed, reflecting good sales performance but issues with profitability and operational efficiency.

Archean Chemical's latest results present a mixed picture. On one hand, the company achieved significant growth in net sales, reaching Rs 345.58 crore, which is a 41.1% increase compared to the average of the previous four quarters. This marks the highest net sales recorded in the last five quarters, indicating a positive trend in sales performance. Additionally, the operating profit before depreciation, interest, and taxes (PBDIT) also reached its highest level in the same period at Rs 88.30 crore.<BR><BR>However, there are notable challenges as well. The profit after tax (PAT) declined by 36.21% year-on-year, which is a concerning drop. Furthermore, the debtors turnover ratio decreased to 6.33 times, suggesting a slowdown in the collection of receivables.<BR><BR>Overall, while the sales figures and operating profit show strong growth, the decline in profit after tax and the decrease in the debtors turnover ratio indicate underlying issues that the company needs to address. Thus, the results can be seen as good in terms of sales growth but concerning regarding profitability and operational efficiency.

When is the next results date for Archean Chemical?

The next results date for Archean Chemical is 14 November 2025.

The next results date for Archean Chemical is scheduled for 14 November 2025.

How has been the historical performance of Archean Chemical?

Archean Chemical's historical performance shows a decline in net sales, operating profit, and profit after tax from March 2023 to March 2025, despite an increase in total assets and liabilities. Cash flow from operating activities also decreased significantly, indicating challenges in profitability and cash generation.

Answer:<BR>The historical performance of Archean Chemical shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Archean Chemical's net sales have experienced a decline from INR 1,441.07 crore in March 2023 to INR 1,041.02 crore in March 2025, with a peak of INR 1,441.07 crore in March 2023. The total operating income followed a similar trend, decreasing from INR 1,441.07 crore in March 2023 to INR 1,041.02 crore in March 2025. The operating profit (PBDIT) also saw a decline, dropping from INR 677.27 crore in March 2023 to INR 351.43 crore in March 2025. Despite this, profit after tax decreased from INR 382.56 crore in March 2023 to INR 162.14 crore in March 2025, indicating a significant reduction in profitability. On the balance sheet, total assets increased from INR 1,531.31 crore in March 2022 to INR 2,389.03 crore in March 2025, while total liabilities rose from INR 1,531.31 crore to INR 2,389.03 crore in the same period. Cash flow from operating activities decreased from INR 496 crore in March 2023 to INR 176 crore in March 2025, reflecting challenges in cash generation. Overall, Archean Chemical's financial performance indicates a decline in revenue and profitability, despite growth in total assets and liabilities.

Should I buy, sell or hold Archean Chemical?

Is Archean Chemical technically bullish or bearish?

As of November 18, 2025, Archean Chemical's trend has shifted to mildly bearish, supported by bearish signals from the MACD, Bollinger Bands, and Dow Theory, despite a mildly bullish daily moving average.

As of 18 November 2025, the technical trend for Archean Chemical has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD and Bollinger Bands both indicating bearish conditions. The Dow Theory also supports this with a mildly bearish signal on both weekly and monthly time frames. Although the daily moving averages show a mildly bullish trend, the overall indicators suggest weakness, particularly with the stock's recent performance against the Sensex, showing a significant decline over the past month and year.

Which are the latest news on Archean Chemical?

Why is Archean Chemical falling/rising?

As of 03-Dec, Archean Chemical Industries Ltd's stock is at 502.65, down 1.06% and has been declining for four consecutive days. The stock has significantly underperformed the market, with a year-to-date decline of 24.97% compared to a 8.92% increase in the Sensex, driven by poor long-term growth and negative investor sentiment.

As of 03-Dec, Archean Chemical Industries Ltd's stock price is falling, currently at 502.65, reflecting a change of -5.4 (-1.06%). The stock has been on a downward trend, losing value for the last four consecutive days and experiencing a total decline of -4.11% during this period. <BR><BR>In terms of performance relative to the market, Archean Chemical has underperformed significantly over various time frames. Over the past week, the stock has decreased by -2.99%, while the Sensex has only fallen by -0.59%. In the last month, the stock has plummeted by -23.47%, contrasting sharply with the Sensex's gain of +1.34%. Year-to-date, the stock has declined by -24.97%, while the Sensex has increased by +8.92%. This trend continues over the past year, with a drop of -28.19% for Archean compared to a +5.27% rise in the Sensex.<BR><BR>The stock's performance is further compounded by several negative factors. The company has reported poor long-term growth, with net sales declining at an annual rate of -6.76% and operating profit falling by -23.20% over the last five years. Additionally, the company has declared negative results for seven consecutive quarters, with a significant drop in operating profit of -20.1% reported in September. The price-to-book value ratio of 3.3 indicates a very expensive valuation, especially given its return on equity (ROE) of just 9. <BR><BR>Investor participation has also decreased, with delivery volume dropping by -82.34% compared to the five-day average, indicating a lack of interest among traders. The stock is trading below its moving averages across all time frames, suggesting a bearish trend. <BR><BR>Despite some positive aspects, such as high management efficiency and low debt levels, these factors are overshadowed by the company's declining financial performance and investor sentiment, leading to the stock's current downward trajectory.